Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)
Serious adverse events · patients with chronic rhinosinusitis with nasal polyps
It is very uncertain whether anti‐IgE mAb (omalizumab) changes serious adverse events compared with placebo (on top of topical steroids) (very low certainty).
1 finding from 1 review
- RR 0.32 [0.05, 2]5 studies · 329 participantsVery low